Skip to main content
Nanalysis Scientific logo

Nanalysis Scientific — Investor Relations & Filings

Ticker · NSCI ISIN · CA63000Y1034 LEI · 529900FGAUUTMJRG1255 TSXV Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2024-06-05 Regulatory Filings
Country CA Canada
Listing TSXV NSCI

About Nanalysis Scientific

https://www.nanalysis.com/

Nanalysis Scientific Corp. is a global developer and manufacturer of compact Magnetic Resonance (MR) technologies, primarily focusing on benchtop Nuclear Magnetic Resonance (NMR) spectrometers and analyzers. The company's proprietary instruments, such as the Nanalysis-60 and Nanalysis-100 platforms, offer accessible, affordable, and automatable high-performance alternatives to traditional high-field NMR systems. This technology democratizes NMR spectroscopy for use in laboratory and industrial settings, including applications in quality assurance/quality control (QA/QC), process analytical technology (PAT), synthetic chemistry, pharmaceuticals, polymers, and academic teaching globally.

Recent filings

Filing Released Lang Actions
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a request form from shareholders to receive financial statements and management discussion and analysis (MD&A) for the fiscal year 2024. It references National Instrument 51-102 regarding continuous disclosure obligations and provides instructions for shareholders to elect to receive annual or interim financial statements and MD&A. The document does not contain any actual financial data, analysis, or report content itself. It is essentially a form for shareholders to request reports, not the reports themselves. The document length is short (3666 characters), and it serves as a communication or request related to financial reports rather than the reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement related to disclosure obligations and shareholder communications, not an actual financial report or announcement of voting results, management changes, or other specific filings.
2024-06-05 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for the Annual General and Special Meeting of Nanalysis Scientific Corp. It includes instructions for appointing a proxyholder to vote on behalf of shareholders at the AGM, details on voting items such as election of directors, appointment of auditors, and approval of the stock option plan. There are no financial statements or detailed financial data present, only proxy voting instructions and meeting logistics. This type of document is used to solicit votes from shareholders prior to the AGM and is not the AGM presentation materials themselves. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is moderate and contains detailed proxy voting information, confirming it is not a brief announcement or a report publication notice.
2024-06-05 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a notice regarding the upcoming Annual General Special Meeting of Nanalysis Scientific Corp., including details such as meeting date, record date, and securities entitled to vote. It does not contain financial data, management discussion, or detailed report content. The document is short (1136 characters) and serves as an announcement of meeting details rather than the meeting materials or results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices related to it.
2024-04-26 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Nanalysis Corp. has received funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop AI software for detection of illicit substances. It describes the project, the company's business, and includes forward-looking statements and disclaimers. There are no financial statements, regulatory certifications, voting results, or management changes. The document is an update on funding and project development, which fits best under Capital/Financing Update (CAP) as it relates to funding received for development activities. The document length is 6484 characters, which is sufficient for a detailed announcement but does not contain financial results or report data. Therefore, the classification is CAP with high confidence.
2024-04-04 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer details, distribution dates, purchaser information, types of securities distributed, compensation information related to the distribution, and jurisdictional breakdowns. This form is a regulatory filing used in Canada to report exempt distributions of securities, which is a compliance and disclosure document rather than a financial report or earnings release. It does not contain financial statements, management discussion, or audit information. The document is lengthy (15,000 characters) and is a formal regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-03-27 English
Offering document (amended) - English.pdf
Capital/Financing Update Classification · 100% confidence The document is titled as an "Amended and Restated Offering Document Under the Listed Issuer Financing Exemption" and contains detailed information about a securities offering, including subscription price, securities offered, closing date, and regulatory disclaimers. It discusses the terms of the offering, the securities involved, and forward-looking statements related to the offering. The document is clearly related to a capital raising activity by the issuer, Nanalysis Scientific Corp., under a specific exemption (NI 45-106) for listed issuer financing. There is no indication that this is a full financial report, audit report, earnings release, or any other type of report. Instead, it is a detailed capital/financing update and offering document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is not a mere announcement or regulatory filing but a substantive offering document.
2024-03-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.